AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|

23.7 C

New York

Thursday, July 23, 2026

EMIRATES ADDS LIKE NASTYA TO ITS AWARD-WINNING ICE INFLIGHT ENTERTAINMENT SYSTEM

Digital Awesome becomes AIQ’s premier mobile app partner for cannabis retailers

Marquis Who’s Who Honors Weiqing Gu, PhD, for Expertise in AI and Healthcare

Tag: Paris:SAN

Press Release: Sanofi Foundation opens new chapter centered on future generations

Sanofi Foundation opens new chapter centered on future generations

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi appoints Paulo Fontoura as Global Head of R&D

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Communiqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la...

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec...

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi launches 2026 global employee stock purchase plan

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Press release: Online availability of Sanofi’s half-year financial report for 2025

Online availability of Sanofi’s half-year financial report for 2025

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Communiqué de presse : Efluelda®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026

Efluelda^®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi: Information concerning the total number of voting rights and shares – June 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsParis:SAN